1 / 13

Neurokinin-1R (SP Receptor) Antagonists for HIV Therapy

Neurokinin-1R (SP Receptor) Antagonists for HIV Therapy. Steven D. Douglas, MD November 16, 2005. Neurokinin-1 receptor antagonist(s) substance P – preferring potential therapeutic pathways. 1. Anti-viral HIV – In vitro and in vivo Cellular mechanism 2. Immunomodulatory

derick
Télécharger la présentation

Neurokinin-1R (SP Receptor) Antagonists for HIV Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Neurokinin-1R (SP Receptor) Antagonists for HIV Therapy Steven D. Douglas, MD November 16, 2005

  2. Neurokinin-1 receptor antagonist(s) substance P – preferring potential therapeutic pathways • 1. Anti-viral HIV – In vitro and in vivo • Cellular mechanism • 2. Immunomodulatory • 3. Anti-depressive behavior

  3. Projects and Cores • Projects: • NK-1R Antagonists – Anti-HIV Mechanisms – Ho • 2. NK-1R Antagonists – Cellular and Molecular • Mechanisms– Douglas, Kilpatrick, Lai • 3. Substance P and NK-1R Antagonists in Simian • AIDS – Lackner, Baker • 4. Human Studies of NK-1R Antagonists in • HIV-1 – Tebas, Orange

  4. Projects and Cores • Cores: • Administrative – Douglas, Tuluc • B. HIV Antiretroviral Drug Susceptibility • and Drug Interactions – Lathey • C. Biostatistics and Pharmacology– Cnaan, Barrett

  5. IPCP Organizational Schema Core A Administration S. Douglas, Dir Internal Advisory Board External Advisory Board Basic Pre-clinical/clinical P1 W-Z Ho, PI P2 S. Douglas, PI P3 A. Lackner, PI P4 P. Tebas, PI Core B Virus Susceptibility J Lathey, Dir Seracare Bioservices (Private Sector Partner) Core C Biostatistics and Pharmacology A. Cnaan, Dir. J. Barrett, Co-Dir.

  6. Internal Advisory Committee • Dr. Peter Adamson, Associate Professor of Pediatrics; • Chief, Div. of Clinical Pharmacology and Therapeutics (CHOP) • 2. Dr. David F. Dinges, Professor of Psychology in Psychiatry; • Chief, Division of Sleep and Chronobiology (UPenn) • 3. Dr. Jonas Ellenberg, Professor of Biostatistics (UPenn) • 4. Dr. Francisco Gonzalez-Scarano, Professor and Chair, • Department of Neurology (UPenn) • 5. Dr. James A. Hoxie, Professor of Medicine, Principal • Investigator of Penn/CHOP/Wistar Center for AIDS Research • 6. Dr.Mark Kramer, Professor of Psychiatry (UPenn) • 7. Dr. David Pleasure, Professor of Neurology (CHOP) • 8. Dr. Rita J. Valentino, Research Prof. of Pediatrics (CHOP)

  7. External Advisory Committee • Dr. Howard Fox, Professor of Neuropharmacology, • The Scripps Research Institute • 2. Dr. Avindra Nath, Professor of Neurology; Director • of Neuroimmunology and Neurological Infections, • Johns Hopkins Medicine • 3. Dr. Janice Clements, Professor and Director, • Comparative Medicine, Johns Hopkins Medicine

  8. Interactions Between Projects Cellular Mechanism P2 P1 Antiviral Antiviral Antiviral Immunomodulatory Immunomodulatory P3 P4 Safety

  9. Substance P(Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2)

  10. Substance P(Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) • SP, described by von Euler and Gaddum in 1931, was the first neuropeptide to be identified. • SP is a neuropeptide comprised of 11 amino acid with a wide-spread distribution in the central and peripheral nervous systems (Chang and Leeman, 1970, 1971). • SP belongs to the tachykinin family that includes SP, neurokinin A (SK), and neurokinin B.

  11. Differential binding sites for substance P and the nonpeptide antagonist CP-96,345 in the NK1 receptor. Hokfelt at al. Journal of Internal Medicine249 (1), 27-40.

More Related